OS Therapies Inc. OSTX 深 滬
等待開盤 07-19 09:30:00 美东时间
1.68
0.000
0.00%
華盛通- 最 高1.7799
- 今 開1.72
- 成交量 22.08万股
- 最 低 1.67
- 昨 收 1.68
- 總市值 4720.41万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.79%
- 52周最低 1.12
- 委 比 84.62%
- 總股本 2809.77万
- 歷史最高 7.00
- 量 比 1.14
- 振 幅 6.54%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.99%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OS Therapies Raises $4.2M Through Warrant Exercise
An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On...
07-14 20:28
OS Therapies Preps for FDA Meeting as It Eyes Accelerated Approval for Rare Bone Cancer Treatment
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a clinical and global regulatory update on its
07-10 19:49
OS Therapies OST-HER2 Demonstrates 35% 12-Month Event Free Survival With Favorable Safety Profile Compared To 20% Historical Control
The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%)Company also
06-30 18:36
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global ...
06-26 23:44
美股大行评级 | 潜在涨幅390.8%！HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级
多家机构首予Amrize买入评级，目标价53~62美元；HC Wainwright & Co.上调内克塔治疗目标价至120美元，维持"买入"评级>>
06-25 08:39
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
06-24 20:12
OS Therapies Selects EVERSANA To Support U.S. Commercialization Of OST-HER2, Immunotherapy For Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma
OS Therapies Inc. (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, has selected EVERSANA®, a leading provider of global
06-10 19:41
OS Therapies Files For Offering Of Up To 7.5M Shares Of Common Stock By Selling Stockholders
-SEC Filing
05-24 04:59
美股大行评级 | 潜在涨幅2840.31%！Mersana Therapeutics获Truist Securities升目标价至10美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities：维持Mersana Therapeutics(MRSN)"买入"评级，目标价从9美元升至10美元</p> <p>• Guggenheim：维持Cabaletta Bio(CABA)"买入
05-17 08:44
OS Therapies Q1 EPS $(0.18) Misses $(0.09) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.09) by 100 percent.
05-16 18:03
